Form 4: OptiNose Executive Paul Spence Jr. Reports Stock and Option Awards

Chief Commercial Officer Paul Spence Jr. of OptiNose, Inc. reports the grant of restricted stock units and stock options.

Summary

• On February 21, 2025, Paul Spence Jr., Chief Commercial Officer of OptiNose, Inc., was granted 17,025 restricted stock units (RSUs) and options to purchase 8,525 shares of common stock.
• The RSUs vest 25% on February 21, 2026, and the remainder in equal quarterly installments over the following three years, contingent upon continued service.
• Each RSU represents the right to receive one share of OptiNose, Inc. common stock.
• The stock options vest 25% on February 21, 2026, and the remainder in equal monthly installments over the following three years, contingent upon continued service.
• The exercise price for the options is $5.77 per share, and they expire on February 21, 2035.
• Following these transactions, Spence directly owns 33,870 shares of common stock and options for 8,525 shares.
• All share numbers reflect the 1-for-15 reverse stock split effected by the Company on December 30, 2024.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. It reflects standard executive compensation practices, which are generally viewed favorably as they align management interests with shareholders.

Positives

• The grant of RSUs and stock options to the Chief Commercial Officer aligns his interests with those of the shareholders.
• The vesting schedules for both RSUs and stock options incentivize continued service with the company.

Industry Context

This filing is a routine disclosure of stock and option awards to a company executive, which is a common practice in publicly traded companies to incentivize and retain key personnel.

Comparison to Industry Standards

• Stock option and RSU grants are standard compensation practices for executives in publicly traded companies, particularly in the pharmaceutical and biotechnology sectors.
• Vesting schedules of four years with a one-year cliff (25% vesting after one year) are also common.
• Comparable companies like Xeris Biopharma and Collegium Pharmaceutical also utilize stock options and RSU grants as part of their executive compensation packages.

Stakeholder Impact

• Shareholders may view the grant of RSUs and stock options as a positive sign, aligning management's interests with the company's long-term success.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates